# QUILT-3.032 (NCT03022825)

> QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: nogapendekin alfa inbakicept (N-803) plus BCG
- Indication: BCG-unresponsive high-grade non-muscle invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03022825
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ImmunityBio, Inc.
- Conditions: Bladder Cancer
- Interventions: N-803 and BCG; N-803
- Enrollment: 190
- Primary outcome: Complete Response
- Primary outcome: Disease-Free Rate

## Questions raised in the commentary

_Automated from the 21 newest of 34 indexed sources (Jul 2019 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether treatment provides benefit beyond the natural history of disease
- Whether papillary-only efficacy can be inferred from data including CIS
- Whether outcomes can be compared reliably across bladder cancer treatments

Also discussed: bladder preservation, IL-15 immune activation, treatment tolerability.

## Indexed commentary on QUILT-3.032 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 20
- Podcasts: 7
- YouTube: 4
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=quilt-3-032-nct03022825

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03022825", "email": "<work email>"}; the inbox owner confirms by the emailed link.